Schizophrenia & Psychotic Disorders

When assessing the value of a reward, people with schizophrenia have difficulty integrating information about the size of the reward and the probability of receiving it, according to a published study.


Vast individual differences in brain structure make the concept of “the average patient with schizophrenia” practically meaningless, suggests a study published online in JAMA Psychiatry.

New guidelines from the European Psychiatric Association promote exercise as a core part of treatment for severe mental illnesses, including major depressive disorder and schizophrenia.

Schizophrenia is a neurodevelopmental, rather than a neurodegenerative disorder, meaning cognitive control deficits are present at onset and not the result of brain deterioration, a new study suggests.

MRI-based predictive tools could inform therapeutic decision making, potentially preventing functional impairment in patients at high clinical risk of psychosis and those with recent-onset depression, researchers say.

Intra-Cellular Therapies, Inc. has submitted a New Drug Application to the US Food and Drug Administration for lumateperone, a investigational medicine with a novel mechanism of action for the treatment of schizophrenia.



John Kane, MD; Ofer Agid, MD; Marjorie L. Baldwin, PhD; Christoph U. Correll, MD; Oliver Howes, MD; Jean-Pierre Lindenmayer, MD; Stephen R. Marder, MD; Mark Olfson, MD, MPH; Steven Potkin, MD
Donna Cox, PhD; Micha Levi, PhD; Laura Rabinovich, PhD; David Truong, PharmD, MS; David Stamler, MD
Ahong Huang, PhD; Tony Amos, PharmD, MS; Kruti Joshi, MPH; Li Wang, PhD; Abigail Nash, MD, PhD
Alex Kopelowicz, MD; Ross A. Baker, PhD, MBA; Cathy Zhao, PhD, MS, BS; Raymond Sanchez, MD; Margaretta Nyilas, MD; Claudette Brewer, BA; Erica Lawson; Timothy Peters-Strickland, MD